TITLE
The Multiple Myeloma Patient Journey: Treatment Sequencing Challenges and Treatment Access Inequities

PROGRAM DESCRIPTION
Multiple myeloma is the second-most-common hematologic malignancy in the United States with approximately 34,470 new cases diagnosed in the United States in 2022. Although multiple myeloma is an incurable disease, numerous active agents are available that, when used in combination, often lead to deep and durable remissions however, the majority of patients with multiple myeloma will eventually relapse. As a result, there has been a dramatic increase in the complexity of care for patients with relapsed/refractory multiple myeloma. To address these gaps and improve the practice of clinicians who treat patients with relapsed/refractory multiple myeloma, this educational intervention will facilitate exchange of information, clinical experience, and practical guidance, while establishing sustainable support networks between the multidisciplinary healthcare team.

INTENDED AUDIENCES
Community-based hematologists, oncologists, fellows, nurse practitioners and physician associates caring for patients with MM

COMMERCIAL SUPPORTER
This activity is supported by an educational grant from Bristol Myers Squibb. 

EDUCATIONAL OBJECTIVES
After taking part in this educational activity, clinicians should become better able to:
Recognize the optimal timing to restart therapy in individual patients with MM in early relapse
Optimize sequencing of therapies for RRMM using clinical data, guidelines, patient preferences and strategies for addressing access barriers
Discuss the safety and efficacy data for new and emerging therapies in RRMM

ACCREDITED PROVIDER & ACCREDIATION STATEMENTS

Accredited by Haymarket Medical Education.

In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENT
Haymarket Medical Education designates this enduring material for a maximum of 3.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

DISCLOSURE OF FINANCIAL RELATIONSHIPS POLICY
Haymarket Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

DISCLOSURE OF UNLABELED USE 
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this IPCE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education and BMS. lease refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme.questions@haymarketmedical.com.

ACCREDITED PROVIDER DISCLOSURE 
None of the planners, reviewers, and Haymarket Medical Education staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.  

METHOD OF PARTICIPATION/INSTRUCTIONS
To obtain credit, a score of 70% or better on the post-assessment is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

Baseline Assessment 0.25 credit
Self Study Module 1 - 0.25 credit
Self Study Module 2 - 0.50 credit
Live Group Discussion 1 - 0.75 credit
Final Assessment - 0.25 credit
Action Plan Development - 0.25 credit
Group Challenge - 0.50 credit
Live Group Discussion 2 - 0.75 credit